Synexus takes part in IBM Excellence in Clinical Planning Seminar

AddThis Feed Button

May 19th, 2009 Leave a comment Visited 28 times, 1 so far today

Following the recent announcement that Synexus has selected IBM Cognos’ performance management solution, Paul McCluskey, Chief Financial Officer, took part in the Excellence in Clinical Planning Seminar in London this week where he addressed a group of leading executives from both pharma and clinical research organizations.

The IBM Cognos solution has been developed in conjunction with Synexus and offers significant benefits across the clinical study lifecycle. The model provides a single, practical platform for planning, forecasting and reporting, in an integrated solution and allows organisations to track all stages of the development and execution of clinical budgets and contract proposals.

Commenting on the new management solution Paul McCluskey said: “We are at the cutting edge in the clinical trials sector and are rapidly and successfully developing a new model that is changing the face of the industry. Adopting this new management solution is imperative if we are to maintain the pace of our growth.”

The new performance management solution is being rolled out across Synexus centres in the UK, Eastern Europe and South Africa in partnership with IBM Cognos and EnterpriseBI Ltd.

Synexus® background

Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment of clinical trials at its own research centres across the globe onbehalf of its pharmaceutical, biotech and CRO clients. Synexus has 16 research centres across the UK, Poland, Hungary, Bulgaria, India and South Africa staffed by full time GCP trained investigators.

Synexus® currently has more than twelve thousand patients enrolled in clinical trials.

Contacts

Vane Percy & Roberts for Synexus
Simon Vane Percy
Office: +44 (0) 1737 821 890/892
Mobile: +44 (0) 7710 005910
Home: +44 (0) 1883 724505
simon {at} vanepercy(.)com





TechWhack on Facebook

Comments are closed.

Related Posts

Popular Posts

blank